Cerebral neoplastic enhancing lesions: Multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0 M) and gadoterate meglumine (0.5 M) at 0.1 mmol Gd/kg body weight in a clinical setting

European Journal of Radiology

Volumn 82, Issue 1, 2013, Pages 139-145

  Anzalone, Nicoletta ^a   Scarabino, Tommaso ^b   Venturi, Carlo ^c   Cristaudo, Concetto ^d   Tartaro, Armando ^e   Scotti, Giuseppe ^a   Zimatore, Domenico ^f   Floris, Roberto ^g   Carriero, Alessandro ^h   Longo, Marcello ⁱ   Cirillo, Mario ^j   Cova, Maria Assunta ^k   Gatti, Simona ^l   Voth, Matthias ^m   Colosimo, Cesare ⁿ  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b L Bonomo Hospital Center   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d CANNIZZARO HOSPITAL   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f BORGO TRENTO HOSPITAL   (Italy)

^g TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^h University Hospital Maggiore della Carita   (Italy)

ⁱ UNIVERSITY OF MESSINA   (Italy)

^j SECOND UNIVERSITY OF NAPLES   (Italy)

^k UNIVERSITY OF TRIESTE   (Italy)

^l Bayer Schering Pharma Division   (Italy)

^m BAYER PHARMA AG   (Germany)

ⁿ FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

more..

Author keywords

Blinded reading; Clinical trial; Diagnostic study; Gadolinium based contrast agents (GBCA); MRI

Indexed keywords

GADOBUTROL; GADOTERATE MEGLUMINE;

ARTICLE; BODY WEIGHT; BRAIN CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; EDEMA; FUNCTIONAL NEUROIMAGING; HUMAN; IMAGE QUALITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIGNAL NOISE RATIO; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT;

BRAIN; BRAIN NEOPLASMS; CONTRAST MEDIA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; OBSERVER VARIATION; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD;

EID: 84871834825     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2011.07.005     Document Type: Article

References (20)

1. P.D. Schellinger, H.M. Meinck, and A. Thron Diagnostic accuracy of MRI compared to CCT in patients with brain metastases J Neurooncol 44 3 1999 275 281
2. P.Y. Wen, and J.S. Loeffler Management of brain metastases Oncology 13 7 1999 941 957
3. W.T. Yuh, T.T. Tali, H.D. Nguyen, T.M. Simonson, N.A. Mayr, and D.J. Fisher The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis AJNR Am J Neuroradiol 16 2 1995 373 380
4. G. Sze, C. Johnson, and Y. Kawamura Comparison of single- and triple-dose contrast material iin the MR screening of brain metastasis AJNR Am J Neuroradiol 19 5 1998 821 828
5. K.R. Maravilla, J.A. Maldjian, and I.M. Schmalfuss Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents Radiology 240 2 2006 389 400
6. N. Anzalone, S. Gerevini, R. Scotti, P. Vezzulli, and P. Picozzi Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine Acta Radiol 50 8 2009 933 940
7. E.S. Kim, J.H. Chang, H.S. Choi, J. Kim, and S.K. Lee Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine AJNR Am J Neuroradiol 31 6 2010 1055 1058 [Epub 2010 Jan 28]
8. M. Voth, U. Attenberger, and A. Luckscheiter "Number needed to read"-How to facilitate clinical trials in MR-angiography Eur Radiol 2010 [Epub 2010 Oct 23]
9. T. Frenzel, P. Lengsfeld, H. Schirmer, J. Hütter, and H.J. Weinmann Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C Invest Radiol 43 12 2008 817 828
10. M.A. Sieber, P. Lengsfeld, and T. Frenzel Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions Eur Radiol 18 10 2008 2164 2173 [Epub 2008 Jun 11]
11. H. Schmitt-Willich Stability of linear and macrocyclic gadolinium based contrast agents Br J Radiol 80 955 2007 581 582
12. M. Rohrer, H. Bauer, J. Mintorovitch, M. Requardt, and H.J. Weinmann Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths Invest Radiol 40 11 2005 715 724
13. J.R. Landis, and G.G. Koch The measurement of observer agreement for categorical data Biometrics 33 1 1977 159 174
14. M.J. Kuhn, P. Picozzi, and J.A. Maldjian Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention J Neurosurg 106 4 2007 557 566
15. U.I. Attenberger, V.M. Runge, J.N. Morelli, J. Williams, C.B. Jackson, and H.J. Michaely Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T Magn Reson Imaging 31 3 2010 549 555
16. T. Engelhorn, M.A. Schwarz, I.Y. Eyupoglu, S.P. Kloska, T. Struffert, and A. Doerfler Dynamic contrast enhancement of experimental glioma: an intra-individual comparative study to assess the optimal time delay Acad Radiol 17 2 2010 188 193 [Epub 2009 Nov 11]
17. N. Anzalone Comparative studies of different gadolinium agents in brain tumors: differences between gadolinium chelates and their possible influence on imaging features AJNR Am J Neuroradiol 31 6 2010 981 982 [Epub 2010 Mar 18]
18. H. Kramer, V.M. Runge, and L.G. Naul Brain MRI with single-dose (0.1 mmol/kg) gadobutrol at 1.5 T and 3 T: comparison with 0.15 mmol/kg gadoterate meglumine AJR Am J Roentgenol 194 5 2010 1337 1342
19. J.O. Balzer, C. Loewe, and K. Davis Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material Eur Radiol 13 9 2003 2067 2074 [Epub 2002 Dec 3]
20. M. Forsting, and P. Palkowitsch Prevalence of acute adverse reactions to gadobutrol - A highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials Eur J Radiol 74 3 2010 186 192 [Epub 2009 Jul 2]